Literature DB >> 12460402

Fluctuations in the peripheral blood leukocyte and platelet counts in leukocytapheresis in healthy volunteers.

Ken Yamaji1, Kwangseok Yang, Hiroshi Tsuda, Hiroshi Hashimoto.   

Abstract

Leukocytapheresis (LCP) for the treatment of patients with diseases that involve an abnormal autoimmune reaction aims to improve the condition of the patient's pathology and to correct imbalances in immunological regulation mechanisms by removing the responsible leukocytes from the peripheral blood. To clarify the mechanism of therapeutic effect, LCP was conducted in healthy volunteers to investigate changes in peripheral blood leukocyte and platelet counts over time during the treatment. The subjects were 10 healthy male volunteers. LCP was performed once in each volunteer for 3,000 ml of blood volume. The peripheral blood counts decreased significantly, reaching a minimum of 20.0% of the baseline number of leukocytes, 10.1% of the baseline number of neutrophils, and 40.3% of the baseline number of lymphocytes. The number of removed leukocytes was about 6.6 x 10(9) cells, including about 3.5 x 10(9) neutrophils, as well as about 5.0 x 10(11) platelets. After the completion of LCP, the peripheral leukocyte levels increased transiently (overshoot), and at 2 h after the completion of the treatment, they reached 193.4% of the baseline value. Since LCP is capable of reducing the peripheral blood leukocyte count over a short period of time, its impact on peripheral blood is great. In addition, in view of the overshoot phenomenon and the appearance of immature granulocytes, the LCP may affect not only the peripheral blood, but also the bone marrow pool, the marginal pool, and the leukocytes present in the tissues.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12460402     DOI: 10.1046/j.1526-0968.2002.00459.x

Source DB:  PubMed          Journal:  Ther Apher        ISSN: 1091-6660


  5 in total

Review 1.  Current topics on therapeutic apheresis.

Authors:  Ken Yamaji
Journal:  J Artif Organs       Date:  2010-04-03       Impact factor: 1.731

2.  Leukocyte removal therapy before surgery in ulcerative colitis.

Authors:  Toshiyuki Matsui
Journal:  J Gastroenterol       Date:  2006-09       Impact factor: 7.527

3.  Gene expression profiles in peripheral blood mononuclear cells of ulcerative colitis patients.

Authors:  Ying-Lei Miao; Yu-Liang Xiao; Yan Du; Li-Ping Duan
Journal:  World J Gastroenterol       Date:  2013-06-07       Impact factor: 5.742

4.  Activated platelets as a possible early marker to predict clinical efficacy of leukocytapheresis in severe ulcerative colitis patients.

Authors:  Ken Fukunaga; Yoshihiro Fukuda; Yoko Yokoyama; Kunio Ohnishi; Takeshi Kusaka; Tadashi Kosaka; Nobuyuki Hida; Yoshio Ohda; Hiroto Miwa; Takayuki Matsumoto
Journal:  J Gastroenterol       Date:  2006-06       Impact factor: 7.527

5.  Modulation of platelet aggregation responses by leukocytapheresis therapy in patients with active ulcerative colitis.

Authors:  Yuhki Yagi; Akira Andoh; Osamu Inatomi; Shigeki Bamba; Tomoyuki Tsujikawa; Yoshihide Fujiyama; Keiichi Mitsuyama; Takashi Yoshida
Journal:  J Gastroenterol       Date:  2006-06       Impact factor: 7.527

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.